This HTML5 document contains 92 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/chemspider/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/chebi/
n21http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/kegg-compound/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/pubchem-substance/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/kegg-drug/
n27http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00651/identifier/national-drug-code-directory/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00651
rdf:type
n3:Drug
n3:description
A theophylline derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis. [PubChem]
n3:dosage
n13:271B61ED-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 hours (range 1.8 - 2.1 hours)
n3:indication
For relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
n3:manufacturer
n6:271B61E5-363D-11E5-9242-09173F13E4C5 n6:271B61E6-363D-11E5-9242-09173F13E4C5 n6:271B61E4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00651 n21:DB00651
dcterms:title
Dyphylline
adms:identifier
n10:PA164748027 n16:3182 n17:D00691 n20:0037-0521-92 n22:46504443 n23:4728 n24:C07819 n25:3070 n26:DB00651
n3:mechanismOfAction
The bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of bronchial smooth muscle as well as antagonism of adenosine receptors.
n3:packager
n6:271B61DE-363D-11E5-9242-09173F13E4C5 n6:271B61E3-363D-11E5-9242-09173F13E4C5 n6:271B61E1-363D-11E5-9242-09173F13E4C5 n6:271B61E2-363D-11E5-9242-09173F13E4C5 n6:271B61DF-363D-11E5-9242-09173F13E4C5 n6:271B61E0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Dyphylline exerts its bronchodilatory effects directly and, unlike the­ophylline, is excreted unchanged by the kidneys without being metabolized by the liver. Approximately 88% of a single oral dose can be recovered from the urine unchanged.
n3:synonym
7-(beta,gamma-Dihydroxypropyl)theophylline Diprophylline (1,2-Dihydroxy-3-propyl)thiophyllin (+-)-Diprophylline 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione Dyphylline 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine (±)-dyphylline 7-(β,γ-dihydroxypropyl)theophylline 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine Dihydroxypropyl theopylin (+-)-7-(2,3-Dihydroxypropyl)theophylline Diprophyllinum 7-(2,3-Dihydroxypropyl)theophylline (±)-diprophylline Diprofilina (+-)-Dyphylline
n3:toxicity
LD<sub>50</sub>=1954 mg/kg (orally in mice)
n3:proteinBinding
84%
n3:synthesisReference
Jones, J.W. and Maney, P.V.; U.S. Patent 2,575,344; November 20,1951; assigned to the State of Iowa.
n11:hasConcept
n12:M0006910
foaf:page
n8:dyphylline.html n27:dyphylline.htm
n3:IUPAC-Name
n4:271B61F2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61F8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61F7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61F4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61F5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61F6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61F0-363D-11E5-9242-09173F13E4C5 n4:271B6208-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61F1-363D-11E5-9242-09173F13E4C5 n4:271B61EE-363D-11E5-9242-09173F13E4C5 n4:271B620A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61EF-363D-11E5-9242-09173F13E4C5 n4:271B620B-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:R03DA01
n3:H-Bond-Acceptor-Count
n4:271B61FE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B61FF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61F9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61FA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61FC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61FB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61FD-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
479-18-5
n3:category
n3:containedIn
n5:271B61E9-363D-11E5-9242-09173F13E4C5 n5:271B61EA-363D-11E5-9242-09173F13E4C5 n5:271B61E7-363D-11E5-9242-09173F13E4C5 n5:271B61E8-363D-11E5-9242-09173F13E4C5 n5:271B61EB-363D-11E5-9242-09173F13E4C5 n5:271B61EC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6204-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6206-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6207-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6209-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6203-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6202-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6205-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61F3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6200-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6201-363D-11E5-9242-09173F13E4C5